Longitudinal changes in a blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in cirrhosis

Background and Aims: Hepatocellular carcinoma (HCC) risk in patients with cirrhosis can be predicted by cross-sectional assessment of biomarkers and/or clinical scores, including the Prognostic Liver Secretome signature (PLSec)-based PAaM score. However, HCC risk may change over time, potentially limiting the accuracy of cross-sectional risk prediction. We aimed to evaluate whether longitudinal changes in HCC risk biomarkers/scores improve upon one-time risk assessment. Approach and Results: In this nested case-control study within the multi-center prospective National Cancer Institute HCC Early Detection Strategy (HEDS) cohort of patients with cirrhosis, we evaluated longitudinal changes in PLSec over 1 or 2 years. Paired baseline and follow-up serum samples were available for 31 cases and 93 controls for 1-year changes, and for 25 cases and 75 controls for 2-year changes. Cross-sectional PLSec scores were higher in cases than in controls at baseline, Year 1, and Year 2 ( p <0.05). The 2-year change in PLSec score (delta-PLSec-Y2) was higher in cases than in controls ( p =0.026; AUROC, 0.65; adjusted odds ratio, 1.47 [95% CI, 1.04–2.15]). In multivariable logistic regression, delta-PLSec-Y2 remained significantly associated with HCC risk ( p =0.041) along with baseline PAaM. Conclusions: Longitudinal assessment of PLSec at a 2-year interval may provide additional information to refine cross-sectional HCC risk assessment, warranting further independent validation, evaluation of longer intervals, and exploration of optimal re-testing frequency.

Authors

Institutions

Publication Details

Journal
Hepatology Communications
Published
2026-11-19
DOI
https://doi.org/10.1097/hc9.0000000000001081
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal changes in a blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in cirrhosis

Stephanie Page-Lester, Yujin Hoshida, Jorge A. Marrero, Amit G. Singal et al.
Hepatology Communications
Hepatocellular Carcinoma Treatment and Prognosis
article

Longitudinal changes in a blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in cirrhosis

Stephanie Page-Lester, Yujin Hoshida, Jorge A. Marrero, Amit G. Singal, Hiroaki Kanzaki, Naoto Fujiwara, Indu Raman, Courtney Katz, Camden Lopez, Lewis Rowland Roberts, K. Rajender Reddy, Neehar D. Parikh, Ziding Feng, Ece Janet Dinç, Hiroyuki Suzuki, Prithvi Raj, Pratibha Selvakumar
article en

Abstract

Background and Aims: Hepatocellular carcinoma (HCC) risk in patients with cirrhosis can be predicted by cross-sectional assessment of biomarkers and/or clinical scores, including the Prognostic Liver Secretome signature (PLSec)-based PAaM score. However, HCC risk may change over time, potentially limiting the accuracy of cross-sectional risk prediction. We aimed to evaluate whether longitudinal changes in HCC risk biomarkers/scores improve upon one-time risk assessment. Approach and Results: In this nested case-control study within the multi-center prospective National Cancer Institute HCC Early Detection Strategy (HEDS) cohort of patients with cirrhosis, we evaluated longitudinal changes in PLSec over 1 or 2 years. Paired baseline and follow-up serum samples were available for 31 cases and 93 controls for 1-year changes, and for 25 cases and 75 controls for 2-year changes. Cross-sectional PLSec scores were higher in cases than in controls at baseline, Year 1, and Year 2 ( p <0.05). The 2-year change in PLSec score (delta-PLSec-Y2) was higher in cases than in controls ( p =0.026; AUROC, 0.65; adjusted odds ratio, 1.47 [95% CI, 1.04–2.15]). In multivariable logistic regression, delta-PLSec-Y2 remained significantly associated with HCC risk ( p =0.041) along with baseline PAaM. Conclusions: Longitudinal assessment of PLSec at a 2-year interval may provide additional information to refine cross-sectional HCC risk assessment, warranting further independent validation, evaluation of longer intervals, and exploration of optimal re-testing frequency.

Hepatology CommunicationsVol. 10(12)
Mayo Clinic (US), Mie University (JP), University of Michigan (US), Fred Hutch Cancer Center (US), Michigan Medicine (US), University of Pennsylvania (US), The University of Texas Southwestern Medical Center (US)
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon